公开(公告)号：WO2023077395A1

公开(公告)日：2023-05-11

申请号：PCT/CN2021/128848

申请日：2021-11-05

申请人： 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所）

发明人： 曾木圣 ,  孔祥炜 ,  胡柱龙 ,  卜国龙 ,  冯国开

IPC分类号： C12N15/86 ,  C12N7/01 ,  G01N33/68 ,  G01N33/569 ,  A61K39/245 ,  A61P31/22

摘要： 一种基于水疱性口炎病毒的EBV疫苗及其制备方法和应用。首次将EBV关键糖蛋白gB和gHgL展示于VSV表面，而且将修饰后的VSV用于动物免疫，提供了一种新的EBV疫苗种类，有望诱导机体产生足够强的免疫反应以防止EBV感染宿主细胞，从而降低EBV相关肿瘤性和非肿瘤性疾病的发病率。检测发现修饰后的VSV能引起显著的、针对EBV表面糖蛋白gB和gHgL的特异性抗体；并且证实了上述产生的特异性抗体可以抑制EBV感染上皮细胞以及B淋巴细胞；也表明了基于VSV的EBV疫苗可以用于防控人群的EBV感染及其相关的肿瘤性和非肿瘤性疾病有很好的免疫效果。

公开(公告)号：WO2021123104A1

公开(公告)日：2021-06-24

申请号：PCT/EP2020/086940

申请日：2020-12-18

申请人： INTERVET INTERNATIONAL B.V. ,  INTERVET INC.

发明人： LANGEREIS, Martijn, Alexander ,  VERSTEGEN, Iwan

IPC分类号： A61K39/12 ,  A61K39/145 ,  A61K39/17 ,  A61K39/245 ,  A61P31/12 ,  A61P31/14 ,  A61P31/16 ,  A61K2039/5256 ,  A61K2039/552 ,  A61K2039/70 ,  C12N2710/16343 ,  C12N2720/10034 ,  C12N2720/10071 ,  C12N2760/16034 ,  C12N2760/16071 ,  C12N2760/18134 ,  C12N2760/18171 ,  C12N2830/34 ,  C12N2830/36

摘要： The present invention describes a recombinant herpesvirus of turkeys (rHVT) that can be used as a vector vaccine for poultry against infection and disease from multiple poultry pathogens. Specifically the rHVT expresses an infectious bursal disease virus (IBDV) viral protein 2 (VP2) gene and a Newcastle disease virus (NDV) fusion (F) protein gene from a first and a second expression cassette inserted in the unique small (Us) region, and expresses an avian influenza virus (AIV) haemagglutinin (HA) gene from a third expression cassette inserted in the unique long (UL) region of the genome of said rHVT either between the UL40 and UL41 genes, or between the UL44 and UL45 genes. This rHVT can be used to vaccinate poultry against MDV, IBDV, NDV and AIV.

公开(公告)号：WO2021038062A1

公开(公告)日：2021-03-04

申请号：PCT/EP2020/074114

申请日：2020-08-28

申请人： EBERHARD KARLS UNIVERSITÄT TÜBINGEN, MEDIZINISCHE FAKULTÄT ,  ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG

发明人： NELDE, Annika ,  LÜBKE, Maren ,  SPALT, Stefanie ,  KOWALEWSKI, Daniel ,  RAMMENSEE, Hans Georg ,  HALENIUS, Anne ,  ZIMMERMANN, Cosima ,  HENGEL, Hartmut ,  BAUERSFELD, Liane ,  LE-TRILLING, Vu Thuy Khanh

IPC分类号： A61K39/245 ,  C07K7/06

摘要： The present invention relates to relates to T cell epitope peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of viral infection. The present invention specifically relates to virus- associated T-cell peptide epitopes, alone or in combination with other virus-associated peptides that can serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-viral immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：WO2020185298A8

公开(公告)日：2020-09-17

申请号：PCT/US2020/013432

申请日：2020-01-14

申请人： MASSACHUSETTS INSTITUTE OF TECHNOLOGY

发明人： WEISS, Ron ,  HOTTELET FOLEY, Maria ,  HUH, Jin ,  JONES, Ross, D.

IPC分类号： C12N15/869 ,  C12N5/10 ,  A61K35/763 ,  A61K39/245

摘要： Provided herein are engineered HSV-1 vectors comprising a modified HSV-1 genome. The engineered HSV-1 vectors can be used to deliver genetic circuits (e.g., up to 100 kb) to cells in vitro or in vivo . Methods of treating or diagnosing a disease (e.g., cancer) using the engineered HSV-1 vectors described herein are also provided.

公开(公告)号：WO2020185298A1

公开(公告)日：2020-09-17

申请号：PCT/US2020/013432

申请日：2020-01-14

申请人： MASSACHUSETTS INSTITUTE OF TECHNOLOGY

发明人： WEISS, Ron ,  HOTTELET, Foley, Maria ,  HUH, Jin ,  JONES, Ross, D.

IPC分类号： C12N15/869 ,  C12N5/10 ,  A61K35/763 ,  A61K39/245

摘要： Provided herein are engineered HSV-1 vectors comprising a modified HSV-1 genome. The engineered HSV-1 vectors can be used to deliver genetic circuits (e.g., up to 100 kb) to cells in vitro or in vivo . Methods of treating or diagnosing a disease (e.g., cancer) using the engineered HSV-1 vectors described herein are also provided.

公开(公告)号：WO2020172522A1

公开(公告)日：2020-08-27

申请号：PCT/US2020/019207

申请日：2020-02-21

申请人： OGEMBO, Javier, Gordon ,  MUTSVUNGUMA, Lorraine, Zvichapera ,  MULAMA, David, H. ,  MUNIRAJU, Murali

发明人： OGEMBO, Javier, Gordon ,  MUTSVUNGUMA, Lorraine, Zvichapera ,  MULAMA, David, H. ,  MUNIRAJU, Murali

IPC分类号： A61K39/245 ,  A61P31/22 ,  C07K14/03 ,  C12N15/38

摘要： Disclosed are vaccine compositions comprising a single KSHV-LP comprising two or more KSHV glycoproteins and/or one or more T cell antigens and methods of preventing or treating KSHV infections using the vaccine compositions. Also disclosed is an expression system or a single expression vector for co-expressing two or more KSHV glycoproteins simultaneously to generate a vaccine comprising a single virus-like particle. The expression system may include a single plasmid inserted with two or more nucleic acid sequences that encode two or more KSHV glycoproteins linked by one or more linking sequences such that the KSHV glycoproteins are co-expressed simultaneously.

公开(公告)号：WO2019241435A1

公开(公告)日：2019-12-19

申请号：PCT/US2019/036841

申请日：2019-06-12

申请人： THE J. DAVID GLADSTONE INSTITUTES

发明人： WEINBERGER, Leor ,  CHATURVEDI, Sonali

IPC分类号： A61K31/711 ,  A61K31/713 ,  A61K39/12 ,  A61K39/245 ,  C07H21/04 ,  C12Q1/68 ,  C12Q1/70

摘要： The present disclosure provides compositions and methods for inhibiting herpesvirus replication in a cell infected with herpesvirus. The composition includes a double stranded DNA molecule including a sequence of a cis regulatory sequence (crs) of a herpesvirus, wherein the crs is flanked on the 5' end by a first sequence of at least 2 base pairs and on the 3' end by a second sequence of at least 2 base pairs.

公开(公告)号：WO2019217922A1

公开(公告)日：2019-11-14

申请号：PCT/US2019/031866

申请日：2019-05-10

申请人： CITY OF HOPE

发明人： WUSSOW, Felix ,  DIAMOND, Don J. ,  CONTRERAS, Heidi

IPC分类号： A61K39/12 ,  A61K39/285 ,  A61K39/245 ,  C12N15/86 ,  C07K14/02 ,  C07K14/045

摘要： A vaccine composition comprising an immunologically effective amount of recombinant modified vaccinia Ankara (rMVA) virus comprising IE1, IE2 and pp65 or antigenic fragments thereof, which is genetically stable after at least 10 passages. A method of improving the stability of such rMVA upon passage by including one or more of the modifications: (1) inserting one or more nucleic acid sequences encoding the CMV antigens or antigenic fragments thereof into one or more insertion sites including but not limited to 044L/045L, IGR3, G1L/I8R, and Del3 but not including Del2; (2) codon optimizing the nucleic acid sequences encoding the CMV antigens by removing consecutive cytosines or guanines; and (3) introducing one or more mutations in the amino acid sequences of the CMV antigens.

公开(公告)号：WO2019173783A1

公开(公告)日：2019-09-12

申请号：PCT/US2019/021469

申请日：2019-03-08

申请人： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA ,  THE UAB RESEARCH FOUNDATION

发明人： BARRY, Peter ,  HARTIGAN-O'CONNOR, Dennis ,  SPARGER, Ellen ,  CHANG, William ,  WALTER, Mark ,  MILLER, Corey

IPC分类号： A61K39/245 ,  C07K14/045 ,  C12N15/38

摘要： In one aspect, the present invention provides recombinant polynucleotides. In some embodiments, the recombinant polynucleotides comprise a cytomegalovirus (CMV) genome, or a portion thereof, and a nucleic acid sequence encoding an antigen, wherein the CMV genome or portion thereof comprises a mutation within a interleukin-10-like gene sequence. Methods for preventing and treating diseases such as infectious diseases and cancer are also provided herein.

公开(公告)号：WO2019165397A1

公开(公告)日：2019-08-29

申请号：PCT/US2019/019489

申请日：2019-02-26

申请人： CORNELL UNIVERSITY

发明人： WAGNER, Bettina

IPC分类号： A61K39/12 ,  A61K39/245 ,  A61K39/42 ,  C12Q1/70

摘要： The present disclosure is directed to novel biomarkers useful for staging EHV-1 infections and immunity status of horses. This disclosure is further directed to methods of determining EHV-1 infection stage and immunity status of horses using the novel biomarkers.